Publications by authors named "Polyxeni Alexiou"

Claim this Profile
S
Serum Transthyretin as Prognostic Biomarker for Cardiovascular Events and Mortality: A Systematic Review and Meta-Analysis.
Dimitrios Terentes-Printzios, Maria Eleni Koilakou, Polyxeni Alexiou, Alexios Antonopoulos, Alexandros Kasiakogias

JACC Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers of COVID-19 Disease Irrespective of Immunosuppression Status: A Case-Control Retrospective Single-Center Study.
Amalia Papanikolopoulou, Vasiliki Rapti, Polyxeni Alexiou, Charalampos M Charalampous, Maria Effrosyni Livanou

Pathogens· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitors: Interpreting the Discrepancy Between Clinical Trials and Real-World Data.
Amalia Papanikolopoulou, Helena Michalopoulou, Konstantinos G Kyriakoulis, Polyxeni Alexiou, Nikolaos Syrigos

Cureus· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulating Sympathetic Nervous System With the Use of SGLT2 Inhibitors: Where There Is Smoke, There Is Fire?
Kyriakos Dimitriadis, Daphne Pitsiori, Polyxeni Alexiou, Nikolaos Pyrpyris, Athanasios Sakalidis

J Cardiovasc Pharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patent Foramen Ovale Closure in Special Clinical Situations: More Questions Than Answers?
Anastasios Apostolos, Polyxeni Alexiou, Amalia Papanikolaou, Georgios Trantalis, Maria Drakopoulou

Life (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Burden of COVID-19 in Adult Patients With Hematological Malignancies: A Single-center Experience After the Implementation of Mass-vaccination Programs Against SARS-CoV-2.
Vasiliki Rapti, Amalia Papanikolopoulou, Georgios Kokkotis, Maria-Effrosyni Livanou, Polyxeni Alexiou

In Vivo· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index.
Vagelis Rinotas, Athanasios Papakyriakou, Foteini Violitzi, Christos Papaneophytou, Maria-Dimitra Ouzouni, Polyxeni Alexiou

J Med Chem· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin.
Marina Sagnou, Fedor N Novikov, Ekaterina S Ivanova, Polyxeni Alexiou, Victor S Stroylov

Eur J Med Chem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of Hydroxyapatite, β-Tricalcium Phosphate and Biphasic Calcium Phosphate Particles to Act as Local Delivery Carriers of Curcumin: Loading, Release and In Vitro Studies.
Despoina Xidaki, Panagiota Agrafioti, Dimitra Diomatari, Archontia Kaminari, Eleftherios Tsalavoutas-Psarras, Polyxeni Alexiou

Materials (Basel)· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aqueous Solubility Enhancement for Bioassays of Insoluble Inhibitors and QSPR Analysis: A TNF-α Study.
Anthi Mettou, Christos Papaneophytou, Georgia Melagraki, Anna Maranti, Fotini Liepouri, Polyxeni Alexiou

SLAS Discov· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit morphine's rewarding effect in rats.
Vicky Katsidoni, Polyxeni Alexiou, Marilena Fotiadou, Maria Pelecanou, Marina Sagnou

Psychopharmacology (Berl)· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationally designed less toxic SPD-304 analogs and preliminary evaluation of their TNF inhibitory effects.
Polyxeni Alexiou, Athanasios Papakyriakou, Evangelos Ntougkos, Christos P Papaneophytou, Fotini Liepouri

Arch Pharm (Weinheim)· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel aldose reductase inhibitors: a patent survey (2006--present).
Maria Chatzopoulou, Polyxeni Alexiou, Eleni Kotsampasakou, Vassilis J Demopoulos

Expert Opin Ther Pat· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A diverse series of substituted benzenesulfonamides as aldose reductase inhibitors with antioxidant activity: design, synthesis, and in vitro activity.
Polyxeni Alexiou, Vassilis J Demopoulos

J Med Chem· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aldose reductase enzyme and its implication to major health problems of the 21(st) century.
Polyxeni Alexiou, Kyriaki Pegklidou, Maria Chatzopoulou, Ioannis Nicolaou, Vassilis J Demopoulos

Curr Med Chem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors.
Polyxeni Alexiou, Ioannis Nicolaou, Milan Stefek, Albin Kristl, Vassilis J Demopoulos

Bioorg Med Chem· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis